S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.39 (-1.34%)
BABA   72.16 (-0.24%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+11.11%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.84%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

Spero Therapeutics (SPRO) Competitors

$1.32
+0.06 (+4.76%)
(As of 12/8/2023 ET)
Compare
Today's Range
$1.25
$1.34
50-Day Range
$1.00
$1.32
52-Week Range
$0.99
$2.04
Volume
218,626 shs
Average Volume
356,209 shs
Market Capitalization
$69.96 million
P/E Ratio
132.00
Dividend Yield
N/A
Price Target
$7.00

SPRO vs. TRVI, CKPT, CLSD, LPTX, BIVI, ACRS, KRON, AFMD, ELYM, and PYXS

Should you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Trevi Therapeutics (TRVI), Checkpoint Therapeutics (CKPT), Clearside Biomedical (CLSD), Leap Therapeutics (LPTX), BioVie (BIVI), Aclaris Therapeutics (ACRS), Kronos Bio (KRON), Affimed (AFMD), Eliem Therapeutics (ELYM), and Pyxis Oncology (PYXS). These companies are all part of the "medical" sector.

Spero Therapeutics vs.

Trevi Therapeutics (NASDAQ:TRVI) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.

76.3% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 27.3% of Spero Therapeutics shares are owned by institutional investors. 27.5% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Trevi Therapeutics has a net margin of 0.00% compared to Trevi Therapeutics' net margin of -2.08%. Trevi Therapeutics' return on equity of 4.14% beat Spero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trevi TherapeuticsN/A -27.16% -24.53%
Spero Therapeutics -2.08%4.14%2.33%

Trevi Therapeutics has higher earnings, but lower revenue than Spero Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevi TherapeuticsN/AN/A-$29.15M-$0.27-4.30
Spero Therapeutics$53.51M1.28-$46.42M$0.01129.00

Trevi Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

In the previous week, Trevi Therapeutics had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 2 mentions for Trevi Therapeutics and 0 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.58 beat Trevi Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Trevi Therapeutics Positive
Spero Therapeutics Neutral

Spero Therapeutics received 123 more outperform votes than Trevi Therapeutics when rated by MarketBeat users. Likewise, 68.88% of users gave Spero Therapeutics an outperform vote while only 59.68% of users gave Trevi Therapeutics an outperform vote.

CompanyUnderperformOutperform
Trevi TherapeuticsOutperform Votes
74
59.68%
Underperform Votes
50
40.32%
Spero TherapeuticsOutperform Votes
197
68.88%
Underperform Votes
89
31.12%

Trevi Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 503.45%. Spero Therapeutics has a consensus price target of $7.00, suggesting a potential upside of 451.18%. Given Spero Therapeutics' higher probable upside, equities analysts clearly believe Trevi Therapeutics is more favorable than Spero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevi Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Spero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Trevi Therapeutics and Spero Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.


Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRO vs. The Competition

MetricSpero TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$68.37M$2.51B$4.62B$6.72B
Dividend YieldN/A3.38%3.00%4.77%
P/E Ratio129.00223.54130.5514.27
Price / Sales1.2810,445.623,066.61530.35
Price / CashN/A12.7221.6523.12
Price / Book0.894.344.724.64
Net Income-$46.42M-$17.88M$124.92M$176.73M
7 Day Performance10.26%0.42%1.11%0.72%
1 Month Performance12.17%2.75%7.17%7.05%
1 Year Performance-29.12%30.29%11.06%7.48%

Spero Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVI
Trevi Therapeutics
2.3848 of 5 stars
$1.07
-3.6%
$7.00
+554.2%
-53.2%$68.33MN/A-3.9625Gap Up
High Trading Volume
CKPT
Checkpoint Therapeutics
1.9491 of 5 stars
$2.90
+0.3%
$24.80
+755.2%
-22.0%$68.24M$190,000.000.0024Positive News
High Trading Volume
CLSD
Clearside Biomedical
1.9005 of 5 stars
$1.11
-0.9%
$5.00
+350.5%
+0.9%$69.28M$1.33M-1.8236Analyst Report
High Trading Volume
LPTX
Leap Therapeutics
2.1173 of 5 stars
$2.72
+3.0%
$17.30
+536.0%
-41.0%$69.55M$1.50M-0.4844
BIVI
BioVie
1.8339 of 5 stars
$1.78
+2.3%
$8.00
+349.4%
-70.5%$67.18MN/A-1.2318Positive News
High Trading Volume
ACRS
Aclaris Therapeutics
2.3461 of 5 stars
$0.99
flat
$23.17
+2,248.6%
-93.4%$69.83M$29.75M-0.59100High Trading Volume
KRON
Kronos Bio
2.2441 of 5 stars
$1.21
+2.5%
$9.00
+643.8%
-27.0%$70.56M$4.00M-0.5899
AFMD
Affimed
2.5226 of 5 stars
$0.44
-2.2%
$5.50
+1,147.2%
-79.1%$65.86M$43.58M-0.52219News Coverage
Gap Up
ELYM
Eliem Therapeutics
2.1146 of 5 stars
$2.51
-3.5%
$6.00
+139.0%
+1.2%$71.69MN/A-1.7130Positive News
PYXS
Pyxis Oncology
2.2154 of 5 stars
$1.65
+0.6%
$8.33
+405.1%
+66.4%$72.69MN/A-0.6567

Related Companies and Tools

This page (NASDAQ:SPRO) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -